Literature DB >> 28495691

Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort.

Els Vandecasteele1, Benny Drieghe2, Karin Melsens3, Kristof Thevissen4, Michel De Pauw2, Ellen Deschepper5, Saskia Decuman3, Carolien Bonroy6, Yves Piette4, Filip De Keyser3,4, Guy Brusselle7, Vanessa Smith3,4.   

Abstract

Screening for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) improves outcomes. The DETECT screening algorithm is recommended in a high-risk SSc subgroup. This study aims to compare prospectively the positive predictive value of screening using the DETECT algorithm and the 2009 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines, and to compare their cost-effectiveness in an unselected, day-to-day SSc population. Post hoc, screening according to the 2015 ESC/ERS guidelines using echocardiographic parameters alone ("2015 echo screening") or combined with the DETECT algorithm ("2015 combined screening") in high-risk subjects was analysed.195 consecutive SSc patients included in the Ghent University Hospital SSc cohort were screened using different algorithms.The referral rate for right heart catheterisation was 32% (63 out of 195 patients) (46/4/13/34/40 patients using the DETECT algorithm/2009 guidelines/both/2015 echo screening/2015 combined screening). Right heart catheterisation was performed in 53 patients (84%) (36 (78%)/four (100%)/13 (100%)/28 (82%)/32 (80%) patients recommended by the DETECT algorithm/2009 guidelines/both/2015 echo screening/2015 combined screening). PAH was diagnosed in three patients (incidence 1.5%·year-1, 95% CI 0.5-4.4), in whom all algorithms recommended a right heart catheterisation. The positive predictive value was 6% (95% CI 2-17%; three out of 49 patients) for the DETECT algorithm, 18% (95% CI 6-41%; three out of 17 patients) for the 2009 guidelines, 23% (95% CI 8-50%; three out of 13 patients) for both, 11% (95% CI 4-27%; three out of 28 patients) for the 2015 echo screening and 9% (95% CI 3-24%; three out of 32 patients) for the 2015 combined screening. The cost was EUR224/80/90/112 per patient using the DETECT algorithm/2009 guidelines/2015 echo screening/2015 combined screening.Echocardiography may remain a candidate first step for PAH screening in SSc.
Copyright ©ERS 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28495691     DOI: 10.1183/13993003.02275-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  15 in total

1.  Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis.

Authors:  Keita Ninagawa; Masaru Kato; Hiroyuki Nakamura; Nobuya Abe; Michihito Kono; Yuichiro Fujieda; Kenji Oku; Shinsuke Yasuda; Hiroshi Ohira; Ichizo Tsujino; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2019-07-06       Impact factor: 2.631

2.  French recommendations for the management of systemic sclerosis.

Authors:  Eric Hachulla; Christian Agard; Yannick Allanore; Jerome Avouac; Brigitte Bader-Meunier; Alexandre Belot; Alice Berezne; Anne-Sophie Bouthors; Geraldine Condette-Wojtasik; Joël Constans; Pascal De Groote; Elisabeth Diot; Florence Dumas; Patrick Jego; Francisca Joly; David Launay; Veronique Le Guern; Janine-Sophie Le Quintrec; Geraldine Lescaille; Christophe Meune; Bruno Moulin; Christelle Nguyen; Nadine Omeish; Frederic Pene; Marie-Aleth Richard; Juliette Rochefort; Alexandra Roren; Olivier Sitbon; Vincent Sobanski; Marie-Elise Truchetet; Luc Mouthon
Journal:  Orphanet J Rare Dis       Date:  2021-07-26       Impact factor: 4.123

3.  Body composition and bone status in relation to microvascular damage in systemic sclerosis patients.

Authors:  V Smith; M Cutolo; S Paolino; E Gotelli; F Goegan; A Casabella; G Ferrari; M Patane; M Albertelli; F Gatto; C Pizzorni; F Cattelan; A Sulli
Journal:  J Endocrinol Invest       Date:  2020-05-24       Impact factor: 4.256

4.  Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension.

Authors:  Amber Young; Vivek Nagaraja; Mark Basilious; Mirette Habib; Whitney Townsend; Heather Gladue; David Badesch; J Simon R Gibbs; Deepa Gopalan; Alessandra Manes; Ronald Oudiz; Toru Satoh; Adam Torbicki; Fernando Torres; Vallerie McLaughlin; Dinesh Khanna
Journal:  Semin Arthritis Rheum       Date:  2018-10-14       Impact factor: 5.532

5.  Unrecognized pulmonary arterial hypertension in hospitalized patients.

Authors:  Andres Mora Carpio; Aaron Goertz; Colleen Kelly; Leslee Willes; Stuart F Quan; Gregg S Pressman; Abesh Niroula; Sunil Sharma
Journal:  Int J Cardiovasc Imaging       Date:  2020-11-19       Impact factor: 2.357

Review 6.  An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature.

Authors:  Sneha M Sundaram; Lorinda Chung
Journal:  Curr Rheumatol Rep       Date:  2018-02-27       Impact factor: 4.592

7.  Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset?

Authors:  Patricia Corzo; Anna Pros; Juana Martinez-Llorens; Luis Molina; Stephanie Fenxi Ling; Eva Balcells
Journal:  Clin Rheumatol       Date:  2018-10-27       Impact factor: 2.980

Review 8.  The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients.

Authors:  Barbara Ruaro; Marco Confalonieri; Francesco Salton; Barbara Wade; Elisa Baratella; Pietro Geri; Paola Confalonieri; Metka Kodric; Marco Biolo; Cosimo Bruni
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-23

Review 9.  Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact.

Authors:  Mario Naranjo; Paul M Hassoun
Journal:  Diagnostics (Basel)       Date:  2021-05-20

10.  Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.

Authors:  Devashis Mukherjee; Girija G Konduri
Journal:  Compr Physiol       Date:  2021-06-30       Impact factor: 8.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.